A Study of Multiple Doses of LY3305677 in Healthy Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: LY3305677

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

16619

I8P-MC-OXAB (Other Identifier)

Details and patient eligibility

About

The purposes of this study are to determine:

The safety of LY3305677 and any side effects that might be associated with it.
How much LY3305677 gets into the bloodstream and how long it takes the body to remove it in healthy participants, including those of Japanese origin.
The effect LY3305677 has on the body, particularly the effect on blood glucose levels.

This study will last approximately 17 weeks not including screening. Screening is required within 4 weeks prior to start of the study.

This study is for research purposes only and is not intended to treat any medical conditions.

Enrollment

56 patients

Sex

All

Ages

20 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Are overtly healthy males or females, as determined by medical history and physical examination
Women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause
Are first-generation Japanese or non-Japanese. First-generation Japanese is defined as the participant, the participant's biological parents, and all of the participant's grandparents are of exclusive Japanese descent and have been born in Japan
Have a body weight of more than 54 kilograms (kg)

Exclusion criteria

Currently enrolled in a clinical study or have participated in a study within the past 3 months
Have an abnormality in the 12-lead electrocardiogram (ECG) at screening
Have history of pancreatitis
Have known or ongoing psychiatric disorders
Have undergone bariatric surgery or have used any drugs for weight loss
Have a history of alcoholism
Currently smoke more than 10 cigarettes a day